You are currently logged into
Hep Directory - My Account or Log Out
Hep Hep
  • Home
  • Basics
    • Basics
    • Introduction
    • Hepatitis A Virus
    • Hepatitis B Virus
    • Hepatitis C Virus
    • NAFLD/NASH
    • Alcoholic Liver Disease
    • Autoimmune Hepatitis
    • Primary Biliary Cholangitis
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Conferences
    • Hep Stories
    • Hep Slideshows
    • Hep TV
    • By Author
    • RSS Links
  • Hot Topics
    • Hot Topics
    • Opioids
    • Hep A Outbreak Map
    • Newly Diagnosed
    • Help Paying for Treatment
    • Hepatitis C Testing
    • Hepatitis C Medications
    • Hepatitis B Testing
    • Hepatitis B Treatment
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • Bulk Subscriptions
    • Email Newsletter
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Community
    • Hep Stories
    • Hep Forums
    • Polls
    • Surveys
    • Ask Hep
    • Services Directory
    • Calendar
    • Bookstore
  • About Us
    • About Us
    • About Us
    • Masthead
    • Awards
    • Advertise
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#Doctors Without Borders

Tweet
  • Share

Generic Hepatitis, HIV and TB Treatments Could Plunge to $90 Each

Such generic drugs could save nations huge sums in the coming years.

Patent Challenges in India and Argentina Target Hepatitis C Treatment

Their aim is to help remove existing barriers to the production and distribution of generic HCV treatment around the world.

Battle Over Patent of Hepatitis C Treatment Begins in India

Lawyers argue that the formula for sofosbuvir was based on “old science” and that the patent should be rejected.

Fighting For Global Access to Hepatitis C Therapies

Battle lines are drawn as the global health community prepares to face off with Big Pharma over the astronomic cost of treatment.

Gilead Is First Drug Company to Join Medicines Patent Pool

Gilead Sciences has expanded its global access program for HBV in developing countries by joining medicines patent pool.

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.